Stressing the vaccine had a "strong safety profile", biotech firm CSL said: "The potential for this cross-reaction had been anticipated prior to the commencement of the trial".
He will be proceeding to Bharat Biotech's facility located at Genome valley, a life sciences cluster about 20 km from the Air Force base, officials said.
Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August.
Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
In a study, published in the Journal of General Internal Medicine, the research team conducted a recent survey of 28 experts working in vaccinology. The survey was carried out in late June 2020.